Macro and Microcirculatory Effects of the Combination of Norepinephrine and Octreotide for the Treatment of Cirrhotic Patients With Hemorrhagic Shock (HemodyNoOc)

Centre Hospitalier Universitaire, Amiens

Status: Withdrawn

Conditions: Variceal Hemorrhage; Haemorrhagic Shock

Treatments: Drug: Octreotide Injection

Study type: Interventional

Funder types: Other

Identifiers

NCT03891849

PI2018_843_0016

Details and patient eligibility

About

Octreotide is used to decrease portal pressure of cirrhotic patients admitted for variceal bleeding. When patients are in haemorrhagic shock, the recommended drug to increase arterial pressure is norepinephrine. Microcirculatory effects of octreotide when it is added to noradrenaline has not been investigated yet. The aim of the study is to evaluate the effect of octreotide plus norepinephrine for patient with haemorrhagic shock after variceal bleeding.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients more than 18 years old
• patient with liver cirrhosis
• patient with haemorrhagic shock due to variceal bleeding
• patient with an arterial blood pressure less than 65 mmHg despite
• patient able to express consent
• signed written informed consent form
• patient covered by national health insurance

Exclusion criteria

• patient less than 18 years old
• patient non covered by national health insurance
• pregnant or breast feeding patent
• known octreotide allergy
• cardiac arrest because of shock
• refused consent

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

octreotide (25 µg/hour) perfusion

Experimental group

Description:

octreotide (25 µg/hour) plus norepinephrine will be administered for patient with haemorrhagic shock after variceal bleeding during 2 to 5 days according recommendations and regular protocol in the medical unit

Treatment:

Drug: Octreotide Injection